CD38 and Miyoshi myopathy: A phase III clinical study (NCT05083169) aimed at evaluating the efficacy of teclistamab in combination with daratumumab, which is a US FDA-approved anti-CD38 mAb, in the treatment of patients with R/R MM is ongoing [284].